Canyon Pharmaceuticals Honored with Frost & Sullivan Award for Product Differentiation Excellence in Parenteral Anticoagulants
Thursday, 27.10.2011

Canyon Pharmaceuticals Honored with Frost & Sullivan Award for Product Differentiation Excellence in Parenteral Anticoagulants

The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants recognizes Canyon Pharmaceuticals Group AG for the development and launch of Iprivask® (desirudin for injection).

“Iprivask has been shown to prevent thrombosis significantly more effectively than the standard of care, with no increase in bleeding risk.  A simplified fixed dose regimen and easy subcutaneous administration coupled with an attractive pharmacological profile make Iprivask ideally suited for the acute care setting, a space in need of safe, effective and user friendly therapies.  Through careful product differentiation during development, Canyon Pharmaceuticals has succeeded in uniquely positioning Iprivask to be very competitive in an increasingly crowded market,” noted Frost & Sullivan Analyst Debbie Toscano. 

 

“Our mission at Canyon Pharmaceuticals is to connect people and science to deliver life-saving medicines that serve today’s unmet needs,” notes Dawn Bell, PharmD, Senior Vice President and General Manager of Canyon’s US subsidiary.  “We worked closely with our acute-care physician and pharmacy colleagues to understand the gaps with current therapies and subsequently launched a highly differentiated anticoagulant that serves critical unmet needs in the hospitalized patient.”

“To achieve this recognition is truly gratifying and a testament to the important unmet needs in the anticoagulant marketplace that Iprivask is able to address,” says Seng Chin Mah, CEO of Canyon Pharmaceuticals Group AG.

About Canyon

 

Canyon PharmaceuticalsTM is a privately held specialty biopharmaceutical company focused on delivering innovative therapeutic solutions that target important cellular pathways in thrombosis, tumor growth, and metastasis. Canyon holds exclusive world-wide rights to desirudin, a subcutaneous (SC) recombinant direct thrombin inhibitor (DTI), and to pegmusirudin, a pegylated recombinant DTI with a longer duration of action than desirudin.

 

Media Contact:
Dr. Seng Chin Mah
E-mail: seng_chin.mahanti spam bot@canyonpharmaanti spam bot.com
Tel: +41 61 201 1383
http://www.canyonpharma.com/

back to list